WINTON GROUP Ltd Reduces Position in Protagonist Therapeutics, Inc. $PTGX

WINTON GROUP Ltd decreased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 38.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,471 shares of the company’s stock after selling 7,090 shares during the quarter. WINTON GROUP Ltd’s holdings in Protagonist Therapeutics were worth $1,002,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Smartleaf Asset Management LLC grew its holdings in shares of Protagonist Therapeutics by 11.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,403 shares of the company’s stock worth $91,000 after buying an additional 146 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares during the period. Oregon Public Employees Retirement Fund grew its holdings in shares of Protagonist Therapeutics by 1.5% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 13,393 shares of the company’s stock valued at $1,170,000 after purchasing an additional 193 shares during the period. PNC Financial Services Group Inc. grew its holdings in shares of Protagonist Therapeutics by 8.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,959 shares of the company’s stock valued at $258,000 after purchasing an additional 221 shares during the period. Finally, Parkman Healthcare Partners LLC grew its holdings in shares of Protagonist Therapeutics by 0.4% in the third quarter. Parkman Healthcare Partners LLC now owns 61,849 shares of the company’s stock valued at $4,109,000 after purchasing an additional 253 shares during the period. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PTGX shares. TD Cowen upped their price objective on shares of Protagonist Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Johnson Rice reissued a “buy” rating on shares of Protagonist Therapeutics in a report on Wednesday, March 18th. Wall Street Zen raised shares of Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, May 9th. Leerink Partners upped their price objective on shares of Protagonist Therapeutics from $107.00 to $110.00 and gave the company an “outperform” rating in a report on Thursday, March 19th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $121.00 price objective on shares of Protagonist Therapeutics in a report on Wednesday, March 18th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $115.21.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director Harold E. Selick sold 24,000 shares of the stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $105.00, for a total transaction of $2,520,000.00. Following the completion of the transaction, the director owned 60,845 shares of the company’s stock, valued at $6,388,725. This trade represents a 28.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bryan Giraudo sold 36,000 shares of the stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $100.14, for a total transaction of $3,605,040.00. Following the sale, the director directly owned 27,825 shares in the company, valued at $2,786,395.50. This represents a 56.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 263,345 shares of company stock valued at $26,707,266 over the last quarter. 5.19% of the stock is owned by insiders.

Protagonist Therapeutics Price Performance

Shares of PTGX stock opened at $105.87 on Wednesday. The firm has a market cap of $6.81 billion, a PE ratio of -58.49 and a beta of 1.85. The company has a 50-day moving average of $101.38 and a two-hundred day moving average of $92.78. Protagonist Therapeutics, Inc. has a 1-year low of $49.38 and a 1-year high of $107.84.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.55. The company had revenue of $56.37 million during the quarter, compared to analyst estimates of $11.70 million. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. Sell-side analysts anticipate that Protagonist Therapeutics, Inc. will post 2.93 EPS for the current fiscal year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.